News
CEO Jacob Thaysen sees Illumina on track to meet his original goal of high single-digit revenue growth by 2027 despite ...
Vaxxas has landed $90 million in debt and equity funding to develop technology that could replace the flu jab and other ...
The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback